Are FINGER trial participants still improving after 4 years?
Yes. Long-term follow-up of the FINGER trial (Finnish Geriatric Intervention Study) presented at AD/PD 2025 showed participants are still getting better at year 4, not just maintaining or slowing decline. This is striking because most Alzheimer prevention interventions at best slow decline. The fact that multi-domain lifestyle changes produce continued cognitive improvement years later suggests real neuroplasticity gains, especially meaningful for APOE4 carriers who respond particularly well to the FINGER protocol.
Why does mild brain atrophy predict better response to lifestyle changes?
Counterintuitive data from AD/PD 2025 showed that people with mild baseline brain atrophy actually respond BETTER to multi-domain lifestyle interventions. One hypothesis is that these individuals have more room for improvement and greater neuroplastic potential. Another is that mild atrophy identifies people whose pathology is still reversible. Either way, the finding challenges the idea that visible brain changes signal a hopeless situation, and suggests lifestyle protocols remain powerful even after early structural change.
What nutrient blend bought patients 21 months of cognitive improvement?
A specific multi-nutrient medical food combining choline, uridine, omega-3 DHA, B vitamins, and phospholipid precursors was shown in human trials to buy patients approximately 21 months of real cognitive improvement measured on standardized tests. This formulation, similar to Souvenaid, targets synaptic membrane formation and is designed to support phosphatidylcholine synthesis. The Phoenix team notes the blend can be approximated with individual supplements, though specific formulation matters for absorption and effect.
What are the 8 AD/PD 2025 breakthroughs APOE4 carriers need to know?
Dr. Kevin Tran identified 8 actionable findings from the AD/PD 2025 Prevention and Therapeutic Interventions session. They span the continued FINGER trial improvement, the surprising atrophy-response finding, the nutrient blend delivering 21 months of gain, precision medicine approaches for APOE4 subgroups, and additional biomarker and protocol insights. These form the basis of an updated Phoenix protocol focused on multi-domain, human-validated interventions rather than theoretical mechanisms.
